Hosted on MSN13h
FDA approves first-ever rapid-acting insulin biosimilar for diabetes treatment
First-ever rapid-acting insulin. This approval extends to a 3-milliliter single-patient-use prefilled pen and a 10-milliliter ...
MedPage Today4d
FDA OKs First Rapid-Acting Insulin Biosimilar for Diabetes
The FDA approved insulin-aspart-szjj (Merilog) as the first rapid-acting insulin biosimilar product to treat adults and ...
Medscape1d
FDA Okays New Rapid-Acting Biosimilar Insulin for Diabetes
The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...
Monthly Prescribing Reference19h
FDA Approves Merilog, a Rapid-Acting Insulin Biosimilar Product
Insulin-aspart-szjj is the first rapid-acting insulin biosimilar approved and the third insulin product approved by the FDA.
Hosted on MSN2d
FDA Approves Groundbreaking Rapid-Acting Insulin Biosimilar Merilog, Offering New Hope for Millions Battling Diabetes
The U.S. Food and Drug Administration (FDA) recently approved Merilog (insulin-aspart-szjj) as the first rapid-acting insulin ...
Medscape1y
Patient Satisfaction and Costs Associated With Insulin Administered by Pen Device or Syringe During Hospitalization
Patients received the FlexPen if they were randomized to the insulin pen group and prescribed any rapid-acting insulin (insulin lispro or insulin aspart) or the combination of 70% insulin aspart ...
FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes
Merilog is the third insulin biosimilar product approved by the FDA and joins the two long-acting insulin biosimilar products ...